Document is current
Any future updates will be listed below
-
Authors
Erkamp, Nadia A. https://orcid.org/0000-0003-4095-2105
Farag, Mina https://orcid.org/0000-0002-6457-6848
Qiu, Yuanxin https://orcid.org/0009-0008-4548-3057
Qian, Daoyuan https://orcid.org/0000-0002-8539-3346
Sneideris, Tomas https://orcid.org/0000-0001-5285-871X
Wu, Tingting
Welsh, Timothy J.
Ausserwöger, Hannes https://orcid.org/0000-0003-0762-8872
Krug, Tommy J.
Chauhan, Gaurav https://orcid.org/0000-0003-2510-8635
Weitz, David A. https://orcid.org/0000-0001-6678-5208
Lew, Matthew D. https://orcid.org/0000-0002-5614-3292
Knowles, Tuomas P. J. https://orcid.org/0000-0002-7879-0140
Pappu, Rohit V. https://orcid.org/0000-0003-2568-1378
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (R01NS121114)
United States Department of Defense | United States Air Force | AFMC | Air Force Office of Scientific Research (FA9550-20-1-0241)
- License Information
-
More Information
Article History
Received: 17 September 2024
Accepted: 1 April 2025
First Online: 11 April 2025
Competing interests
: R.V.P. is a member of the scientific advisory board of and shareholder in Dewpoint Therapeutics Inc. T.P.J.K. is the co-founder of Fluidic Analytics, Wren Therapeutics, Xampla, and Transition Bio. These associations did not influence the work reported here. The remaining authors declare no competing interests and none of the authors have any non-financial interests to declare.
